In 2025, Caliway Biopharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Caliway Biopharmaceuticals has also provided a category-level breakdown for 2 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 9.772a | N/A | N/A | |
Total Scope 2 | ||||
Market-Based | 760.473b | N/A | N/A | |
Location-Based | N/A | N/A | N/A | |
Unspecified Calculation Method | N/A | 710.278a | 639.154a | |
Total Scope 3 | 161.283a | N/A | N/A | |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Caliway Biopharmaceuticals amounted to 770.245 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).ab
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Caliway Biopharmaceuticals increased by 8.44%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab
In 2025, the total Scope 1 emissions of Caliway Biopharmaceuticals were 9.772 metric tons of CO₂ equivalent (tCO₂e).a
In 2025, Caliway Biopharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 760.473 tCO₂e using the market-based method.b
In 2025, Caliway Biopharmaceuticals reported its Scope 2 emissions using the market-based method.b
In 2025, Caliway Biopharmaceuticals reported 161.283 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Caliway Biopharmaceuticals includes a breakdown across 2 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2025, Caliway Biopharmaceuticals reported total Scope 3 emissions of 161.283 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
In 2025, Caliway Biopharmaceuticals reported emissions for 2 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2025, the largest contributors to Caliway Biopharmaceuticals's Scope 3 emissions were:a
In 2025, Caliway Biopharmaceuticals reported a total carbon footprint of 931.528 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 31.15% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Caliway Biopharmaceuticals's total carbon footprint was Scope 2 emissions, accounting for 81.64% of the company's total carbon footprint, followed by Scope 3 emissions at 17.31%.ab